DEPRENYL USA COMMENCES INITIAL CONTROLLED HUMAN CLINICAL TRIALS
/REPEATING FOR POINTS NEEDED/ PARSIPPANY, N.J., March 4 /PRNewswire/ -- Deprenyl USA, Inc.
(NASDAQ: DUSA) reports that Phase I/IIA human clinical trials for ALA Photodynamic Therapy (PDT) cm?enced the week of Feb. 21 at the University of California, Irvine. The principal investigator is Dr. Gerald Weinstein, head of the Department of Dermatology at the university. The University of California, Irvine, is a renowned center for the investigation of advanced dermatology treatment techniques, such as photodynamic therapy.
Three separate human trials are involved, totalling more than 100 patients. The purpose of the research is to determine the clinically effective dosages of drug and light required to treat actinic keratoses and psoriasis. These studies involve a variety of protocols contained in the company's Investigational New Drug (IND) submission to the FDA which became effective in January 1993. Deprenyl USA is a development stage company established to bring prescription pharmaceutical products to worldwide markets, initially in the United States and Canada and primarily in the field of photodynamic therapy. Common stock and warrants are traded on NASDAQ under the symbols DUSA and DUSAW. They also trade on the Toronto Stoca?nge under the symbols DPU and DPU.WT. -0- 3/4/93 /CONTACT: Toronto Office: Geoffrey Shulman, MD, president & CEO, 416-537-1070, or fax, 416-537-0258; Joseph P. Castelli, vice president, 201-299-9070, or fax, 201-335-0372, both of Deprenyl USA; Jim Tolan, sr. vice president, or Nicholas Biro, partner, 708-498-2284, or fax, 708-498-3144, both of O'Connor Biro & Associates, for Deprenyl USA/ (DUSA)
CO: Deprenyl USA, Inc. ST: New Jersey IN: MTC SU:
LR -- NY024 -- 3276 03/05/93 02:20 EST
|Printer friendly Cite/link Email Feedback|
|Date:||Mar 5, 1993|
|Previous Article:||HANSEN NATURAL CORP. (HANS) ANNOUNCES EXTENSION OF CLASS A WARRANTS|
|Next Article:||FEBRUARY SALES INCREASE 4.5 PERCENT FOR THE MAY DEPARTMENT STORES COMPANY|